| EGFR status | Objective response | Chi-2 | |||
| Complete or partial response | Stable disease | Progressive disease | Not evaluable | P | |
| Dako test* |
|
|
|
|
|
| negative (N = 131) | 29 (22%) | 35 (27%) | 53 (40%) | 14 (11%) | 0.788 |
| positive (N = 201) | 48 (24%) | 44 (22%) | 85 (42%) | 24 (12%) |
|
| All IHC tests† |
|
|
|
|
|
| Full-negative cases (N = 86) | 21 (24%) | 24 (28%) | 30 (35%) | 11 (13%) | 0.507 |
| All other cases (N = 246) | 56 (23%) | 55 (22%) | 108 (44%) | 27 (11%) |
|
| Total (N = 332) | 77 | 79 | 138 | 38 |
|